Literature DB >> 3193322

Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns.

S L Schulman1, B A Kaiser, M S Polinsky, R Srinivasan, H J Baluarte.   

Abstract

To determine the utility of steroid response in classifying childhood nephrotic syndrome, we reviewed 119 biopsies in 92 children aged 1 to 16 years who had been followed for a mean of 7.2 years. Steroid responses were classified as steroid resistant, steroid dependent, and frequent relapser as defined by the International Study of Kidney Disease in Children. Biopsy specimens were classified as showing focal glomerulosclerosis (FSGS) in 39 children, as showing lipoid nephrosis in 28, and as questionable in another 25 with either focal global sclerosis, IgM nephropathy, or mesangial prominence and tubular changes. A strong agreement (p less than 0.01) was found between children whose FSGS was steroid resistant and children whose lipoid nephrosis resulted in frequent relapses. The length of the remission after therapy with chlorambucil or cyclophosphamide was determined in 84 children. A significantly shorter length of remission after cytotoxic drug therapy (p less than 0.05) was identified for patients with FSGS versus those with lipoid nephrosis; this difference became more significant for steroid-resistant patients in comparison with those who were steroid dependent or were frequent relapsers (p less than 0.005). Among all steroid-resistant patients, those with FSGS had shorter remissions than patients with other histologic changes (p less than 0.001). The data suggest that patterns of response to corticosteroid therapy correlate with the histologic abnormality. Thus steroid-sensitive patients need not undergo renal biopsy before receiving cytotoxic drugs. Steroid-resistant patients would benefit from a biopsy, because the findings tend to predict the outcome.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3193322     DOI: 10.1016/s0022-3476(88)80570-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  21 in total

1.  Urine proteomic profiling of pediatric nephrotic syndrome.

Authors:  Mona Khurana; Avram Z Traum; Manuel Aivado; Meghan P Wells; Manuel Guerrero; Franck Grall; Towia A Libermann; Asher D Schachter
Journal:  Pediatr Nephrol       Date:  2006-06-30       Impact factor: 3.714

2.  Mutational analysis of NPHS2 and WT1 in frequently relapsing and steroid-dependent nephrotic syndrome.

Authors:  Rasheed Gbadegesin; Bernward Hinkes; Christopher Vlangos; Bettina Mucha; Jinhong Liu; Jeff Hopcian; Friedhelm Hildebrandt
Journal:  Pediatr Nephrol       Date:  2007-01-10       Impact factor: 3.714

Review 3.  Update on the treatment of focal segmental glomerulosclerosis in renal transplantation.

Authors:  Maria Messina; Ester Gallo; Alberto Mella; Fabiola Pagani; Luigi Biancone
Journal:  World J Transplant       Date:  2016-03-24

4.  Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.

Authors:  Piero Ruggenenti; Barbara Ruggiero; Paolo Cravedi; Marina Vivarelli; Laura Massella; Maddalena Marasà; Antonietta Chianca; Nadia Rubis; Bogdan Ene-Iordache; Michael Rudnicki; Rosa Maria Pollastro; Giovambattista Capasso; Antonio Pisani; Marco Pennesi; Francesco Emma; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2014-01-30       Impact factor: 10.121

5.  Do C1q or IgM nephropathies predict disease severity in children with minimal change nephrotic syndrome?

Authors:  Mateja Vintar Spreitzer; Alenka Vizjak; Dušan Ferluga; Rajko B Kenda; Tanja Kersnik Levart
Journal:  Pediatr Nephrol       Date:  2013-07-13       Impact factor: 3.714

6.  Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.

Authors:  Xiao-Ling Niu; Sheng Hao; Ping Wang; Wei Zhang; Gui-Mei Guo; Ying Wu; Xin-Yu Kuang; Guang-Hua Zhu; Wen-Yan Huang
Journal:  Biomed Rep       Date:  2016-06-30

7.  Kidney biopsy prior to cyclophosphamide therapy in primary nephrotic syndrome.

Authors:  T K Mattoo
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

8.  B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.

Authors:  Manuela Colucci; Rita Carsetti; Simona Cascioli; Federica Casiraghi; Annalisa Perna; Lucilla Ravà; Barbara Ruggiero; Francesco Emma; Marina Vivarelli
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

Review 9.  Focal segmental glomerulosclerosis.

Authors:  I Ichikawa; A Fogo
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

Review 10.  Serum suPAR in patients with FSGS: trash or treasure?

Authors:  Rutger J H Maas; Jeroen K J Deegens; Jack F M Wetzels
Journal:  Pediatr Nephrol       Date:  2013-03-21       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.